by AACR
Findings from the Phase 3 AURIGA trial support the use of lenalidomide plus daratumumab (D-R) over lenalidomide alone (R) as post-transplant maintenance therapy for patients with newly diagnosed...
by Alex Kadhim
Researchers at SickKids Hospital and McMaster University have developed a novel chimeric antigen receptor (CAR) T-cell therapy targeting ROBO1, a protein involved in axonal guidance, for the...
by Nature Medicine
Researchers report that while autologous chimeric antigen receptor (CAR) T-cell manufacturing is possible in the setting of acute myeloid leukemia (AML), myeloid-supporting cytokines released...
by ASH Publications
Evidence suggests ciltacabtagene autoleucel (cilta-cel) generates a durable response in patients with relapsed/refractory multiple myeloma, even those who would not have qualified for...
by ImmonuoHorizons
Researchers have identified a promising new platform for preclinical testing of chimeric antigen receptor (CAR) T cell efficacy against solid tumors.
by Blood Advances
Early evidence supports a deeper look into candidate chimeric antigen receptor (CAR) T-cell therapies for the treatment of relapsed and refractory B-cell acute lymphoblastic leukemia (B-ALL) in...